drugset / Trial / NCT02345772

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

NCT02345772

Phase 1/2 Terminated 4 enrolled Western Regional Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.

Timeline

Start
2014-07
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2
Subject Fulvestrant Small molecule 500 mg Intramuscular
Subject Pertuzumab Monoclonal antibody 420 mg
Subject Trastuzumab Monoclonal antibody 6 mg/kg